61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals ...Middle East

STOCKHOLM, May 24, 2024 /PRNewswire/ -- A pioneering study, presented today at the 61st ERA Congress, has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and...

Hence then, the article about 61st era congress semaglutide significantly reduces risk of major kidney disease events cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease groundbreaking study reveals was published today ( Friday 24/05/2024 - 02:01 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( 61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals )

Also on site :

• Retired Gen. Wesley Clark tangled up in a crypto fraud suit with Burning Man buddies
• 1965 Timeless Classic Ranked Among ‘Greatest Country Songs of All Time’ Became a Long-Running No. 1 Hit
• Iran-US war latest: Trump extends pause on energy plant strikes and says talks with Tehran going ‘very well’